# TLS ENGINEERING DOCTRINE: STATUS & DOCUMENTATION INDEX

**Last Updated:** October 2024  
**Purpose:** Consolidated overview of all TLS engineering documentation, strategic positioning, and partnership materials  
**Status:** ðŸŸ¢ **COMPLETE & PARTNER-READY**

---

## **I. DOCUMENT ECOSYSTEM OVERVIEW**

The TLS Engineering Doctrine consists of **4 core documents** organized in the `/MM/TLS/` folder:

### **1. `intel.mdc` - Raw Intelligence from MSK Presentation**

**Type:** Scientific Intel / Discovery Summary  
**Length:** 59 lines  
**Purpose:** Document MSK's 10-year spatial immunology findings as presented by their researcher  
**Audience:** Internal team, for understanding the scientific foundation  

**Key Content:**
- MSK's three grand challenges (Good Soil, Spark, Context)
- TLS spectrum (lymphoid aggregates â†’ mature TLS with GCs)
- C-MSC sabotage mechanism (TGFÎ², TWIST1, IDO1)
- Her current approach (CD40L oncolytic virus)

**Status:** âœ… **Complete** - This is the raw material from the MSK speaker's presentation

---

### **2. `tls.mdc` - Complete TLS 101 Educational Doctrine**

**Type:** Comprehensive Technical + Biological Education  
**Length:** 1,042 lines  
**Purpose:** Transform TLS discovery science into engineering doctrine with full implementation plan  
**Audience:** Internal team, technical partners, immunology researchers  

**Structure:**
- **Part I-X (Educational):** TLS biology, clinical data, C-MSC sabotage, our weapons, partner value, roadmap (530 lines)
- **Part III (Implementation):** APIs, orchestration, validation, wet-lab mapping (180 lines)
- **Part IV-VI (Strategic):** Frontend demo, positioning, achievability (120 lines)

**Key Sections:**
1. **TL;DR:** 60-second brief
2. **Part I:** The $50B Question (why immunotherapies fail)
3. **Part II:** TLS 101â€”The Biology (anatomy, spectrum, clinical data)
4. **Part III:** The Enemyâ€”C-MSCs (sabotage mechanism)
5. **Part IV:** Our Solution (3 weapons: TLS Readiness, Stromal Cassette, Molecular Staple Gun)
6. **Part V:** Weapons Arsenal Summary (operational status)
7. **Part VI:** What This Means for Partners (3 audiences)
8. **Part VII:** Brutal Honesty (limitations: bulk confidence LOW, stromal unproven)
9. **Part VIII:** Roadmap (Q4 2024 â†’ 2026)
10. **Part IX:** Bottom Line
11. **Part X:** Usage Guide

**Plus Implementation Plan:**
- 7 Core APIs (TLS Readiness, C-MSC Mining, Stromal Cassette, GC Forcing, Spatial Validation, Delivery Vector, Feedback)
- Orchestration flow (`/api/tls/orchestrate`)
- In-silico validation stack
- Wet-lab validation plan
- Risks & guardrails
- Reproducibility & provenance

**Status:** âœ… **Complete** - Publication-grade educational resource

---

### **3. `TLS_MSK_PARTNERSHIP.mdc` - Executive Partnership Positioning**

**Type:** Strategic Partnership Document  
**Length:** 850+ lines  
**Purpose:** Position CrisPRO as MSK's engineering partner for TLS therapeutics  
**Audience:** MSK leadership, department heads, clinical trial PIs  

**Structure:**
1. **Executive Summary:** "You discovered the battlefield. We engineer it."
2. **I. The Foundation:** MSK's 10-year discovery (clinical data, TLS spectrum, C-MSC sabotage)
3. **II. Value Proposition:** 5 solutions mapped to MSK's challenges (table format)
4. **III. Partnership Flywheel:** Closed-loop learning (spatial data trains our models)
5. **IV. The 8-Week Pilot:** Prove it (50 patients, zero risk, full deliverables)
6. **V. Why Now?** (Strategic timing, urgency, risk of waiting)
7. **VI. Stakeholder Messaging:** Tailored messages for PIs, clinicians, leadership
8. **VII. Objection Handling:** 5 likely objections with crisp responses
9. **VIII. Next Steps:** Clear path forward (immediate actions, milestones, long-term vision)
10. **IX. One-Page Executive Summary:** TL;DR for C-suite

**Key Features:**
- **IP & Credit:** Clear terms (MSK retains discovery IP, joint IP on novel designs, 70/30 revenue split)
- **8-Week Pilot:** Detailed protocol (data inputs, deliverables, cost: $0)
- **Objection Handling:** Pre-emptive responses to "Why do we need bulk RNA?" / "What if designs fail?"
- **Stakeholder Messaging:** Customized value props for 3 audiences

**Status:** âœ… **Complete** - Executive-ready, partnership discussion document

---

### **4. `TLS_MSK_INFOGRAPHIC.mdc` - Visual Presentation Blueprint**

**Type:** 6-Slide Deck Blueprint  
**Length:** 600+ lines  
**Purpose:** Distill TLS partnership into a compelling 10-minute visual pitch  
**Audience:** MSK leadership, clinical teams, spatial immunology PIs  

**Slide Structure:**
1. **Slide 1:** The Foundation (MSK's 10-year discovery, survival data table)
2. **Slide 2:** The Problem (3-panel: Observation Gap, Sabotage Problem, Intervention Gap)
3. **Slide 3:** The Solution (3 columns: TLS Readiness, Stromal Cassette, Molecular Staple Gun)
4. **Slide 4:** The Partnership Model (flywheel diagram, IP boxes)
5. **Slide 5:** The 8-Week Pilot (timeline, deliverables, cost/terms)
6. **Slide 6:** Why MSK? Why Now? (3 urgencies: Opportunity, Urgency, Risk)

**Plus:**
- **Appendix:** Stakeholder-specific messaging (one-liners for PIs, clinicians, leadership)
- **Visual Style Guide:** Fonts, colors, icons, data visualization standards
- **Presentation Script:** 10-minute delivery with timing (90 sec per slide)

**Design Principles:**
- Tone: Professional, collaborative, evidence-backed (not competitive)
- Color Palette: MSK brand (deep blue, slate gray) + CrisPRO accent (cyan, electric blue)
- Key Message: "You discovered the battlefield. We engineer it. Together, we terraform immune deserts."

**Status:** âœ… **Complete** - Screen-recording ready, presentation-grade

---

## **II. KEY STRATEGIC DECISIONS & ANSWERS**

### **Partnership Model: Collaborative Co-Invention (Not Vendor)**

**What MSK Provides:**
- Spatial TLS data (Visium/CODEX) - 50 patients for 8-week pilot
- Clinical outcomes (survival, treatment response)
- Wet-lab validation (C-MSC organoid models, flow cytometry)

**What CrisPRO Provides:**
- Engineering tools (TLS Readiness Score, Stromal Cassette, GC Forcing)
- Design algorithms (patient-specific targeting)
- Regulatory support (Pre-IND safety packages)

**What We Build Together:**
- Bulkâ†’Spatial translator (Tier 3 learning: spatial data trains our models)
- Clinical trials (Phase I: Stromal Cassette + Checkpoint Blockade)
- Joint publications (Nature Med, Cell, JCO)
- Joint IP (novel designs: 70% MSK, 30% CrisPRO revenue split)

---

### **8-Week Pilot: Zero-Risk Proof of Concept**

**Inputs (MSK):**
- 50 ovarian cancer patients: bulk RNA + spatial Visium + TLS annotations
- Timeline: 2 weeks for data transfer

**Deliverables (CrisPRO, Week 8):**
1. **TLS Readiness Score for all 50 patients** (validated vs spatial ground truth, target: r > 0.70)
2. **10 patient-specific stromal cassettes** (top TLS-low patients, with safety scans)
3. **Pre-IND safety package** (off-target analysis, immunogenicity, vector selection)
4. **Calibration report** (model performance, error analysis, improvement roadmap)

**Cost:** $0 (no upfront fee)  
**IP:** MSK retains all data; joint IP on novel designs; if pilot fails, MSK keeps all deliverables  
**Exit Clause:** Either party can exit with 2-week notice (no penalties)

---

### **Brutal Honesty: What We Admit (Out Loud)**

**Limitation 1: Bulk RNA Confidence is LOW**
- TLS Readiness Score from bulk RNA is ~0.3-0.4 correlation with spatial ground truth
- We label predictions with tiered confidence (LOW/MED/HIGH)
- We recommend spatial validation for high-stakes clinical decisions

**Solution:** Spatial data trains our bulkâ†’spatial translator (Tier 3 learning). Over time, bulk confidence improves (0.3 â†’ 0.5 â†’ 0.7).

**Limitation 2: Stromal Cassette is Unproven in Humans**
- CRISPRi + TF reprogramming has never been tested in human C-MSCs
- We have strong pre-clinical rationale (organoid models) but no Phase I data

**Solution:** 8-week pilot tests C-MSC cassettes in organoid models first. If successful, IND-enabling studies follow (6-12 months).

**Limitation 3: GC Forcing is Mechanistic, Not Validated**
- CD19Ã—CD40L fusion has pre-clinical data (humanized mouse models)
- But optimal dose, schedule, combination strategy are unknown

**Solution:** Phase I trial (12-18 months) with dose escalation and spatial imaging endpoints (GC density, TLS maturity).

**Limitation 4: We Need Your Spatial Data**
- Tier 3 learning requires large spatial datasets (n > 100 patients)
- Without them, Tier 1 (bulk) stays at LOW confidence forever

**Solution:** MSK's spatial data is the strategic asset. Partnership gives us access; learning loop gives MSK proprietary models.

---

## **III. WEAPONS ARSENAL: CURRENT STATUS**

### **Category 1: Ready Now (Operational)**

| **Weapon** | **Problem Solved** | **How** | **Timeline** | **Status** | **API** |
|-----------|-------------------|---------|-------------|-----------|---------|
| **TLS Readiness Score** | Spatial imaging slow/expensive (4 weeks, $2K) | Bulk RNA â†’ TLS/GC prediction (8 min, $100) | <1 hour design | âœ… Operational | `/api/tls/score_readiness` |
| **C-MSC Target Mining** | Don't know which saboteurs to target | Patient-specific ranking (TGFÎ²R2, TWIST1, IDO1) | <2 hours design | âœ… Operational | `/api/tls/identify_cmsc_targets` |
| **GC Forcing Fusion** | B-T conjugation is random chance | CD19Ã—CD40L staple gun â†’ force GC | <2 hours design | âœ… Design-ready | `/api/tls/force_gc_design` |

### **Category 2: In the Forge (6-18 Months)**

| **Weapon** | **Problem Solved** | **How** | **Timeline** | **Status** | **Next Milestone** |
|-----------|-------------------|---------|-------------|-----------|-------------------|
| **Stromal Cassette** | C-MSCs sabotage TLS | CRISPRi (de-program) + TF (re-program) | IND: 6-12 months | ðŸŸ¡ Pre-clinical | Organoid validation (8-week pilot) |
| **Spatial Validation** | Bulk confidence LOW | Visium/CODEX â†’ HIGH confidence upgrade | Integration: 1-2 months | ðŸŸ¡ In progress | Ingest 50 MSK spatial samples |
| **Tier 1 Feedback** | Models don't learn | Wet-lab results â†’ calibration updates | Implementation: 3-6 months | ðŸ”´ Requires partners | MSK wet-lab data ingestion API |

---

## **IV. ROADMAP: WHAT GETS BUILT WHEN**

### **Q4 2024 (Now)**
- âœ… TLS Readiness Score (operational)
- âœ… C-MSC Target Mining (operational)
- âœ… GC Forcing Fusion Design (design-ready)
- ðŸ”µ **MSK Partnership Docs Complete** (this milestone)

### **Q1-Q2 2025 (Next 6 Months)**
- ðŸŸ¡ 8-Week Pilot with MSK (50 ovarian patients)
- ðŸŸ¡ Stromal Cassette IND-enabling studies (organoid validation)
- ðŸŸ¡ Tier 2 Spatial Integration (Visium/CODEX ingestion)
- ðŸŸ¡ Co-authored manuscript prep (if pilot succeeds)

### **Q3-Q4 2025 (6-12 Months)**
- ðŸ”´ First-in-human trial (Stromal Cassette in ovarian cancer, MSK lead PI)
- ðŸ”´ GC Forcing Phase I (CD19Ã—CD40L fusion, humanized mouse â†’ patient)
- ðŸ”´ Tier 3 Transfer Learning (bulkâ†’spatial predictor trained on n > 100 spatial datasets)

### **2026 (12-24 Months)**
- ðŸ”® Combination trials (Stromal Cassette + Checkpoint Blockade)
- ðŸ”® CAR-T synergy studies (TLS pre-conditioning in solid tumors)
- ðŸ”® First joint MSK publication (Nature Med, Cell, or JCO)

---

## **V. METRICS & SUCCESS CRITERIA**

### **Technical Metrics (8-Week Pilot)**

**TLS Readiness Score Validation:**
- **Target:** Correlation r > 0.70 between predicted and spatial-measured TLS density
- **Baseline:** Current bulk RNA deconvolution methods achieve r â‰ˆ 0.3-0.4
- **Acceptance:** r > 0.70 = publication-grade; r > 0.60 = proceed with caution; r < 0.60 = iterate

**Stromal Cassette Design:**
- **Target:** â‰¥40% C-MSCâ†’FDC conversion in organoid models (flow cytometry: CD21+, CXCL13+)
- **Baseline:** Current CD40L virus achieves â‰ˆ20-30% conversion
- **Acceptance:** â‰¥40% = IND-enabling; 30-40% = optimize; <30% = redesign

**Safety Validation:**
- **Off-target Hits:** â‰¤5 genome-wide (BLAST + minimap2)
- **Immunogenicity:** Zero high-affinity junctional epitopes (NetMHCpan rank > 2%)
- **Vector Tropism:** Liver/heart off-target < 10%

---

### **Business Metrics (12-24 Months)**

**Publications:**
- **Target:** 1-2 co-authored papers (MSK lead, CrisPRO co-author)
- **Journals:** Nature Med, Cell, JCO, Science Translational Medicine

**IP Generation:**
- **Target:** 2-3 joint patent applications (TLS Readiness algorithm, stromal cassette designs)
- **Licensing:** Explore licensing to CAR-T companies (for TLS pre-conditioning)

**Clinical Trials:**
- **Target:** 1 Phase I trial initiated (Stromal Cassette in ovarian cancer)
- **Lead:** MSK (PI), CrisPRO (co-sponsor)

---

## **VI. DOCUMENT USAGE GUIDE**

### **For Internal Team (CrisPRO)**

**Before MSK Partnership Call:**
- Read `TLS_MSK_PARTNERSHIP.mdc` (Executive Summary + Value Proposition)
- Review `TLS_MSK_INFOGRAPHIC.mdc` (6-slide deck + presentation script)

**Before Technical Deep Dive:**
- Read `tls.mdc` (Part II: TLS Biology + Part IV: Our Solution)
- Review implementation plan (Part III: APIs, orchestration, validation)

**Before Design Reviews:**
- Read `tls.mdc` (Part III: The Enemyâ€”C-MSCs) to understand sabotage mechanism
- Review weapons arsenal (Part V) and roadmap (Part VIII)

---

### **For MSK Partners**

**First Exposure (Leadership):**
- Read `TLS_MSK_PARTNERSHIP.mdc` (Executive Summary, Section IX: One-Page Summary)
- Review `TLS_MSK_INFOGRAPHIC.mdc` (Slide 1, 6 only for quick context)

**Technical Validation (PIs, Spatial Immunology Team):**
- Read `tls.mdc` (TL;DR + Part II: TLS Biology + Part IV: Our Solution)
- Review implementation plan (APIs, validation, wet-lab mapping)

**Clinical Trial Design (Trial PIs):**
- Read `TLS_MSK_PARTNERSHIP.mdc` (Section IV: 8-Week Pilot + Section VI: Stakeholder Messaging for Clinicians)
- Review `tls.mdc` (Part VI: What This Means for Partners â†’ Immunotherapy Trials section)

---

### **For Investors/Board**

**Due Diligence:**
- Read `TLS_MSK_PARTNERSHIP.mdc` (Executive Summary + Section II: Value Proposition)
- Review `tls.mdc` (Part VII: Brutal Honesty + Part VIII: Roadmap)

**Market Positioning:**
- Read `TLS_MSK_INFOGRAPHIC.mdc` (Slide 3: Solution, Slide 6: Why Now?)
- Review competitive differentiation (competitors observe TLS; we engineer them)

---

## **VII. NEXT ACTIONS**

### **Immediate (This Week)**

**For CrisPRO Team:**
- [ ] Internal review of all 4 documents (technical lead, business dev, regulatory)
- [ ] Prepare data sharing agreement template (HIPAA-compliant, de-identified)
- [ ] Draft 8-week pilot protocol (objectives, methods, acceptance criteria)

**For MSK Outreach:**
- [ ] Identify MSK champion (likely their TLS/spatial immunology lead)
- [ ] Schedule 60-min intro call (leadership + PI team)
- [ ] Send `TLS_MSK_PARTNERSHIP.mdc` as pre-read (Executive Summary only)

---

### **Near-Term (Next 4-8 Weeks)**

**If MSK Expresses Interest:**
- [ ] Deep-dive technical call (2 hours: walk through `tls.mdc` implementation plan)
- [ ] Present 6-slide deck (use `TLS_MSK_INFOGRAPHIC.mdc` as script)
- [ ] Finalize data sharing agreement (legal teams)
- [ ] Kick off 8-week pilot (data transfer, QC, analysis)

**If MSK Declines:**
- [ ] Request feedback: What would make this compelling? What data/evidence is missing?
- [ ] Pivot to alternate partners (Stanford spatial immunology, Penn CAR-T group)
- [ ] Iterate docs based on feedback

---

### **Mid-Term (3-6 Months)**

**If Pilot Succeeds (r > 0.70 for TLS Readiness):**
- [ ] Co-author manuscript: "Prospective TLS Prediction from Bulk RNA in Ovarian Cancer"
- [ ] Submit to Nature Medicine or Cell
- [ ] Design Phase I trial: Stromal Cassette + Checkpoint Blockade (MSK lead PI, CrisPRO co-sponsor)
- [ ] Expand dataset: 200 patients (NSCLC, breast, melanoma) for cross-cancer validation

**If Pilot Partially Succeeds (r = 0.50-0.70):**
- [ ] Error analysis: Where does model fail? What data would improve it?
- [ ] Upgrade to Tier 2: Add scRNA-seq for 50 patients â†’ Re-validate
- [ ] Iterate: Retrain model, repeat validation

**If Pilot Fails (r < 0.50):**
- [ ] Full post-mortem: Document failure modes, share learnings
- [ ] MSK retains all code/algorithms/designs (no strings attached)
- [ ] Publish negative results (optional co-authorship: "Limitations of Bulk RNA for TLS Prediction")

---

## **VIII. SUMMARY: WHAT WE ACCOMPLISHED**

### **TLS Doctrine Ecosystem: COMPLETE âœ…**

**4 Documents Created:**
1. âœ… `intel.mdc` - Raw MSK presentation intel (59 lines)
2. âœ… `tls.mdc` - Complete educational + implementation doctrine (1,042 lines)
3. âœ… `TLS_MSK_PARTNERSHIP.mdc` - Executive partnership positioning (850+ lines)
4. âœ… `TLS_MSK_INFOGRAPHIC.mdc` - 6-slide visual presentation blueprint (600+ lines)

**Total:** 2,550+ lines of comprehensive TLS engineering documentation

---

### **Strategic Positioning: PARTNER-READY**

**Key Messages Established:**
- "You discovered the battlefield. We engineer it."
- "We don't observe TLS. We build them. On demand. Patient-specifically."
- "MSK's spatial data trains our models. Learning loop gives MSK proprietary tools."

**Objection Handling: PRE-EMPTED**
- 5 likely objections addressed with crisp, evidence-backed responses
- Brutal honesty about limitations (bulk confidence LOW, stromal unproven)
- Clear exit clauses (2-week notice, no penalties, MSK keeps all deliverables)

**Partnership Model: DEFINED**
- 8-week pilot (50 patients, zero risk, full deliverables)
- IP & credit (MSK retains discovery, joint IP on designs, 70/30 revenue split)
- Closed-loop learning (spatial data â†’ bulkâ†’spatial translator â†’ proprietary models)

---

### **Technical Readiness: OPERATIONAL**

**3 Weapons Ready:**
- âœ… TLS Readiness Score (8 min vs 4 weeks, `/api/tls/score_readiness`)
- âœ… C-MSC Target Mining (patient-specific, `/api/tls/identify_cmsc_targets`)
- âœ… GC Forcing Fusion (CD19Ã—CD40L, `/api/tls/force_gc_design`)

**Roadmap: REALISTIC**
- Q4 2024: Complete partnership docs (DONE)
- Q1-Q2 2025: 8-week pilot, IND-enabling studies
- Q3-Q4 2025: First-in-human trial (Stromal Cassette)
- 2026: Combination trials, joint publication, clinical validation

---

## **IX. COMPARISON TO TOX DOCTRINE**

### **Similarities (What We Replicated)**
- âœ… Comprehensive educational blog (`tls.mdc` = `tox101-blog.mdc`)
- âœ… Executive partnership positioning (`TLS_MSK_PARTNERSHIP.mdc` = MSK Executive Positioning in `tox.mdc`)
- âœ… Visual infographic blueprint (`TLS_MSK_INFOGRAPHIC.mdc` = MSK Infographic in `tox.mdc`)
- âœ… Brutal honesty section (limitations admitted out loud)
- âœ… Stakeholder-specific messaging (PIs, clinicians, leadership)
- âœ… Clear roadmap with timelines (Q4 2024 â†’ 2026)

### **Differences (TLS-Specific)**
- **TLS focuses on battlefield architecture** (not T-cell exhaustion)
- **Enemy is C-MSCs** (not Tox/TCF1 paradox)
- **3 weapons instead of 6** (TLS Readiness, Stromal Cassette, GC Forcing vs Tox arsenal)
- **Partnership is with MSK spatial immunology** (not MSK T-cell exhaustion team)
- **Clinical gap is 70-80% TLS-poor tumors** (not CAR-T exhaustion)

---

**Doctrine Status:** ðŸŸ¢ **COMPLETE, PARTNER-READY, & STRATEGICALLY POSITIONED**  
**Next Action:** Schedule MSK partnership discussion call and present 6-slide deck.  
**Last Updated:** October 2024
